Download PDF
Dtsch Med Wochenschr 2001; 126(Suppl. Gastroenterol. 1): S52-S58
DOI: 10.1055/s-2001-14492
Supplement Gastroenterologie (1)
© Georg Thieme Verlag Stuttgart · New York

Zytokin- und Antizytokintherapien bei chronisch entzündlichen Darmerkrankungen

Treatment of chronic inflammatory disease with cytokines and anticytokines B. M. Wittig, M. Zeitz
  • Medizinische Klinik I (Gastroenterologie, Infektiologie, Rheumatologie), Universitätsklinikum Benjamin Franklin, Freie Universität Berlin
Further Information

Publication History

Publication Date:
11 September 2002 (online)

Also available at
    Permissions and Reprints

Morbus Crohn und Colitis ulcerosa sind die häufigsten immunologisch vermittelten gastroenterologischen Erkrankungen. Funktionell wird eine chronisch persistierende Immunantwort beobachtet, die sich von der regulierten Aktivierung des intestinalen Immunsystems unter physiologischen Bedingungen oder bei akuten Infektionen unterscheidet [47] [56] . Als Pathomechanismus wird ein enges Zusammenspiel zwischen genetischer Suszeptibilität des Patienten, der mukosalen Immunregulation und der mikrobiologischen Darmflora vermutet.

Literatur

  • 1 Akbar A, Lord J M, Salmon M. IFN-α and IFN-β: a link between immune memory and chronic inflammation.  Immunol Today. 2000;  21 337-342
    Google Scholar
  • 2 Arnott I DR, Shand A, Ghosh S. Administration of Infliximab in Crohn’s disease does not deplete complement components C3 an C4.  Am J Gastroenterol. 2000;  95 3320-3321
    Google Scholar
  • 3 Beutler B, Krochin N, Milsark I W, Luedke C, Cerami A. Control of cachectin (tumour necrosis factor) protects mice from lethal effect of endotoxin.  Science. 1986;  232 977-980
    Google Scholar
  • 4 Bickston S J, Lichtenstein G R, Arseneau K O, Cohen R B, Cominelli F. The relationship between infliximab treatment and lymphoma in Crohn’s disease.  Gastroenterology. 1999;  117 1433-1437
    Google Scholar
  • 5 Brandtzaeg P, Farstad I N, Haraldsen G. Regional specialization in the mucosal immune system; primed cells do not always home along the same track.  Immunol Today. 1999;  6 267-277
    Google Scholar
  • 6 Braunstein J, Qiao L, Autschbach F, Schürmann G, Meuer S. T cells of the human intestinal lamina propria are high producers of interleukin-10.  Gut. 1997;  41 215-220
    Google Scholar
  • 7 Choy E H, Rankin E C, Kassimos D. et al . The engineered human anti-tumor necrosis factor-alpha antibody CDP571 inhibits inflammatory pathways but not T cell activation in patients with rheumatoid arthritis.  J Rheumatol. 1999;  26 2310-2317
    Google Scholar
  • 8 Cohen R D, Tsang J F, Hanauer S B. Infliximab in Crohn’s disease: first anniversary clinical experience.  Am J Gastroenterol. 2000;  95 3469-3477
    Google Scholar
  • 9 D’Haens G, Swijsen C, Noman M, Lemmens L, Geboes K, Rutgeerts P. Etanercept (TNF receptor fusion protein, Enbrelš) is effective and well tolerated in active refractory Crohn’s disease: Results of a single center pilot trial.  Gastroenterology (Abs.). 2000;  118 3600
    Google Scholar
  • 10 Desreumaux P, Brandt E, Bambiez L. et al . Distinct cytokine pattern in early and chronic ileal lesions of Crohn’s diease.  Gastroenterology. 1997;  113 118-126
    Google Scholar
  • 11 Ehrenpreis E D, Kane S V, Cohen L B, Cohen R D, Hanauer S B. Thalidomide therapy for patients with refractory Crohn’s disease: an open-label trial.  Gastroenterology. 1999;  117 1271-1277
    Google Scholar
  • 12 Eigler A, Loher F, Endres S. Suppression der Synthese des Tumornekrosefaktor.  Der Internist. 2001;  42 28-34
    Google Scholar
  • 13 Evans R C, Clarke L, Heath P, Stephens S, Morris A I, Rhodes J M. Treatment of ulcerative colitis with an engineered anti-TNFα antibody CDP571.  Aliment Pharmacol Ther. 1997;  11 1031-1035
    Google Scholar
  • 14 Farrell R J, Ang Y, Kileen P. et al . Increased incidence of non-Hodgkin’s lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low.  Gut. 2000;  47 514-519
    Google Scholar
  • 15 Farrell R J, Shah S A, Lodhavia P J. et al . Clinical experience with infliximab therapy in 100 patients with Crohn’s disease.  Am J Gastroenterol. 2000;  95 3490-3497
    Google Scholar
  • 16 Fedorak R N, Gangl A, Elson C O. et al . Recombinant human interleukin 10 in the treatment of patients with mild to moderate active Crohn’s disease.  Gastroenterology. 2000;  119 1473-1482
    Google Scholar
  • 17 Fuss I J, Neurath N, Boirivant M. et al . Disparate CD4+ lamina propria lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5.  J Immunol. 1996;  157 1261-1270
    Google Scholar
  • 18 Gasche C, Reinisch W, Vogelsang H. et al . Prospective evaluation of interferon-alpha in treatment of chronic active Crohn’s disease.  Dig Dis Sci. 1995;  40 800-804
    Google Scholar
  • 19 Geißler M, Blum H E. Therapeutische monoklonale Antikörper.  Dtsch Med Wschr. 2000;  125 1501-1504
    Google Scholar
  • 20 Kempeni J. Update on D2E7: A fully human anti-tumour necrosis factor alpha monoclonal antibody.  Ann Rheum Dis. 2000;  59 i44-i45 (suppl))
    Google Scholar
  • 21 Kugathasan S, Werlin S L, Martinez A, Rivera M T, Heikenen J B, Binion D G. Prolonged duration of response to infliximab in early but not late pediatric Crohn’s disease.  Am J Gastroenterol. 2000;  95 3189-3194
    Google Scholar
  • 22 Lochs H, Adler G, Beglinger C. et al . Anti-TNF antibody in Crohn’s disease - status of information, comments and recommendations of an international working group.  Z Gastroenterol. 1999;  37 509-512
    Google Scholar
  • 23 Maini R N, Elliott M, Brennan F M, Williams R O, Feldmann M. Targeting TNF alpha for the therapy of rheumatoid arthritis.  Clin Exp Rheumatol. 1994;  12 S63-S66 (Suppl 1))
    Google Scholar
  • 24 Marth T, Zeitz M. Konventionelle und immunmodulatorische Therapie bei chronisch-entzündlichen Darmerkankungen.  Dtsch Med Wschr. 1999;  124 1173-1177
    Google Scholar
  • 25 Menghini V V, Arora A S. Infliximab-associated reversible cholestatic liver disease.  Mayo Clin Proc. 2001;  76 84-86
    Google Scholar
  • 26 Moreland L W, Baumgartner S W, Schiff M H. et al . Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p-75)-Fc fusion protein.  N Engl J Med. 1997;  340 1398-1405
    Google Scholar
  • 27 Neurath M, Fuss I, Kelsall B L, Stüber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice.  J Exp Med. 1995;  182 1281-1290
    Google Scholar
  • 28 Nicolaus S, Raedler A, Kuhbacker T, Sfikas N, Fölsch U R, Schreiber S. Mechanisms in failure of infliximab for Crohn’s disease.  Lancet. 2000;  356 1475-1479
    Google Scholar
  • 29 Poltorak A, Peppel K, Beutler B. Receptor-mediated label-transfer assay (RELAY) - a novel method for the detection of plasma tumor necrosis factor at attomolar concentrations.  J Immunol Methods. 1994;  169 93-99
    Google Scholar
  • 30 Present D H, Rutgeerts P, Targan S. et al . Infliximab for the treatment of fistulas in patients with Crohn’s disease.  N Engl J Med. 1999;  340 1398-1405
    Google Scholar
  • 31 Qiao L, Braunstein J, Golling M. et al . Differential regulation of human T cell responsiveness by mucosal versus blood monocytes.  Eur J Immunol. 1996;  26 922-927
    Google Scholar
  • 32 Qiu B S, Pfeiffer C J, Keith J CJ. Protection of recombinant human interleukin-11 against experimental TNB-induced colitis in rats.  Dig Dis Sci. 1996;  41 1625-1630
    Google Scholar
  • 33 Ricart E, Pannaccione R, Loftus E V, Tremaine W J, Sandborn W J. Successful management of Crohn’s disease of the ileoanal pouch with infliximab.  Gastroenterology. 1999;  117 429-432
    Google Scholar
  • 34 Rogler G, Brand K, Vogl D. et al . Nuclear factor kappa B is activated in macrophages and epithelial cells of inflamed intestinal mucosa.  Gastroenterology. 1998;  115 357-369
    Google Scholar
  • 35 Rutgeerts P, D’Haens G, Targan S. et al . Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (Infliximab) to maintain remission in Crohn’s disease.  Gastroenterology. 1999;  117 761-769
    Google Scholar
  • 36 Sandborn W J, Hanauer S B. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety.  Inflamm Bowel Dis. 1999;  5 119-133
    Google Scholar
  • 37 Sands B E. Therapy of inflammatory bowel disease.  Gastroenterology. 2000;  118 S68-S82 (Suppl)
    Google Scholar
  • 38 Sands B E, Bank S A, Sninsky C A. et al . Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn’s disease.  Gastroenterology. 1999;  117 58-64
    Google Scholar
  • 39 Sands B E, Podolsky D K, Tremaine W J. et al . Chimeric monoclonal anti-tumor necrosis factor alpha antibody (cA2) in the treatment of severe, steroid-refractory ulcerative colitis.  Gastroenterology. 1996;  110 A1008
    Google Scholar
  • 40 Schieferdecker H L, Ullrich R, Hirseland H, Zeitz M. T cell differentiation antigens on lymphocytes in human intestinal lamina propria.  J Immunol. 1992;  149 2816-2822
    Google Scholar
  • 41 Schölmerich J. Which immunosuppressors do you use to treat Crohn’s diseae and ulcerative colitis? In which order of priority and how worried are you about toxicity?.  Inflamm Bowel Dis. 1998;  4 248-252
    Google Scholar
  • 42 Schreiber S, Fedorak R N, Nielson O H. et al . Safety and efficacy of recombinant human interleukin-10 chronic active Crohn’s disease.  Gastroenterology. 2000;  119 1461-1472
    Google Scholar
  • 43 Schreiber S, Fedorak R N, Wild G. et al . Safety and tolerance of rHuIL-10 treatment in patients with mild/moderate active ulcerative colitis.  Gastroenterology. 1998;  114 A1079
    Google Scholar
  • 44 Sheldon D G, Sawchuk L L, Kozarek R A, Thirlby R C. Twenty cases of peristomal pyoderma gangrenosum.  Arch Surg. 2000;  135 564-569
    Google Scholar
  • 45 Soykan I, Ertan C, Özden A. Severe anaphylactic reaction to infliximab: Report of a case.  Am J Gastroenterol. 2000;  95 2395-2396
    Google Scholar
  • 46 Stack W A, Mann S D, Roy A J. et al . Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn’s disease.  Lancet. 1997;  349 521-524
    Google Scholar
  • 47 Strober W, Fuss I J, Erhardt R O, Neurath M, Boirivant M, Ludviksson B R. Mucosal immune regulation and inflammatory bowel disease: new insights from murine models of inflammation.  Scand J Immunol. 1998;  48 453-458
    Google Scholar
  • 48 Strober W, Neurath M F. Immunological diseases of the gastrointestinal tract. l. St. Louis: Mosby In: Rich, R. R., Ed. Book 1995: 1401-1428
    Google Scholar
  • 49 Sümer N, Palabiyikoglu M. Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis.  Eur J Gastroenterol Hepatol. 1995;  7 597-602
    Google Scholar
  • 50 Targan S R, Hanauer S B, van Deventer S JH. et al . A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group.  N Engl J Med. 1997;  337 1029-1035
    Google Scholar
  • 51 van Deventer S JH, Elson C O, Fedorak R N. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn’s disease. Crohn’s Disease Study Group.  Gastroenterology. 1997;  113 383-389
    Google Scholar
  • 52 van Dullemen H M, van Deventer S JH, Hommes D W. et al . Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).  Gastroenterology. 1995;  109 129-135
    Google Scholar
  • 53 Vantrappen G, Coremans G, Billiau A, De Somer P. Treatment of Crohn’s disease with interferon. A preliminary clinical trial.  Acta Clin Belg. 1980;  35 238-242
    Google Scholar
  • 54 Vasiliauskas E A, Kam Y L, Abreu-Martin M T. et al . An open-label pilot study of low-dose thaliomide in chronically active, steroid-dependent Crohn’s disease.  Gastroenterology. 1999;  117 1278-1287
    Google Scholar
  • 55 Vermeire S, Monsuur F, Groenen P, Peeters M, Vlietinck R, Rutgeerts P. Response to anti-TNFα-treatment is associated with the TNF-308.1 allele.  Gastroenterology. 2000;  118 3595
    Google Scholar
  • 56 Zeitz M. Pathogenesis of inflammatory bowel disease.  Digestion. 1997;  58 59-61 (Suppl 1))
    Google Scholar
  • 57 Zeitz M, Schieferdecker H L, Ullrich R, Jahn H U, James S P, Riecken E O. Phenotype and function of lamina propria T cells.  Immunol Res. 1991;  10 199-206
    Google Scholar

Korrespondenz

Prof. Dr. M. Zeitz

Direktor der Medizinische Klinik I (Gastroenterologie, Infektiologie, Rheumatologie)
Universitätsklinikum Benjamin Franklin Freie Universität Berlin

Hindenburgdamm 30

12200 Berlin

Phone: 030/8445-2347

Phone: 030/8445-4481

Email: zeitz@ukbf.fu-berlin.de